Prime Stock alert: Moving this tonnage stock to a HOLD
We are moving an industrial sector stock that we recommended in June 2022, to a HOLD.
Prime Recommendation: A thematic fund to add in long-term portfolios
Propelled by economic growth, along with signs of recovery, the underlying theme of this fund makes for a good long-term option now.
Prime Stock alert: Moving this healthcare play to a HOLD on swift up move
We are moving this Prime Stock to a HOLD and this report will explain why.
Quarterly review – changes to Prime Funds and Prime ETFs
In this quarter’s review of our recommendations, we have made 3 fund additions and a few removals from our Prime Funds and ETFs Prime ETFs list.
FMCG sector: At the crossroads
Around this time last year, we had analysed the FMCG sector’s March 2022 quarter earnings. At the time, the sector was grappling with twin headwinds of a demand slump and rising input costs. Valuations were still expensive. Most FMCG players have declared their results for the March 2023 quarter.
Prime Stock Recommendation: An R&D focused company in the API space
It has been a rough ride for the Indian API industry in the past 2 years. A combination of factors including price erosion in US generics, destocking, demand fluctuation, elevated raw material costs and freight costs have hit the margins of many API plays including market favourites such as Divi’s, Laurus and Aarti Drugs. Their growth has also remained at low single digits in this period.
Still, if a company has managed to remain resilient in this period and yet corrected to valuations that make it attractive, it deserves to be noticed.
What has changed with REIT/InvIT taxation
For Indian investors looking for regular income with the possibility of capital appreciation, Real Estate Investment Trusts (REITs) and Infrastructure Investment Trusts (InvITs) are good vehicles. These entities own a bunch of real estate or infrastructure assets that throw up regular cash flows and distribute over 90% of their cash flows to their investors. As both their income and the value of the real estate or infrastructure portfolio they own can rise over time, REITs and InvITs offer the prospect of rising income with capital gains.
Prime NCD Review: An NCD with attractive yields across timeframes
With capital gains on debt fund investments now subject to short-term capital gains tax irrespective of holding period, other debt instruments have become quite competitive with debt mutual funds.
Mankind Pharma IPO: Invest or avoid?
Mankind Pharma, which operates in the domestic pharmaceuticals space, opens its Rs 4300 core IPO today. The issue is priced at a band of Rs 1,026 – Rs 1,080 per share of face value Re.1/-.
Prime stocks update: An exit call on an insurance stock
In April 2022, we had issued a buy recommendation on a general insurance player, as both the industry and the company itself were emerging from the Covid-driven impact and were poised for growth. Since then, however, the insurance sector has lost market favour as growth has not panned out as expected.
Prime Stocks update: Moving this biotech stock from BUY to a HOLD
When we gave the call of this R&D focused company engaged in the manufacture of enzymes and probiotics, the company had Covid-related challenges but showed promise of growth. It was later also pulled down by consolidation of acquisitions and costs related to new product launches. We therefore knew that the call would take longer to pay off. The stock went through a significant correction after our initial recommendation as earnings disappointed.